Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis

Marston, 2016, Antimicrobial resistance, JAMA, 316, 1193, 10.1001/jama.2016.11764 Golan, 2015, Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options, BMC Infect Dis, 15, 313, 10.1186/s12879-015-1054-1 Gupta, 2011, Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention, Clin Infect Dis, 53, 60, 10.1093/cid/cir202 Rubio Lopez, 2017, Carbapenemase-producing Enterobacteriaceae in the intensive care unit, Intensive Care Med Exp, 5, 44 Trecarichi, 2017, Therapeutic options for carbapenem-resistant Enterobacteriaceae infections, Virulence, 8, 470, 10.1080/21505594.2017.1292196 Ehmann, 2012, Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor, Proc Natl Acad Sci U S A, 109, 11663, 10.1073/pnas.1205073109 Hidalgo, 2016, Ceftazidime/avibactam: a novel cephalosporin/nonβ-lactam β-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections, Drug Des Devel Ther, 10, 2379, 10.2147/DDDT.S110946 Riccobene, 2012, A single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaroline fosamil plus avibactam (CXL) administered by intravenous (IV) infusion to healthy subjects, Pharmacotherapy, 32, e212 ClinicalTrials.gov. NCT01689207. To investigate the safety and tolerability of aztreonam–avibactam (ATM-AVI). https://www.clinicaltrials.gov/ct2/show/NCT01689207?term&NCT01689207&rank=1 [accessed 25 January 2018]. ClinicalTrials.gov. NCT02655419. Determine the PK and safety and tolerability of ATM-AVI for the treatment of cIAIs in hospitalized adults (REJUVENATE). https://www.clinicaltrials.gov/ct2/show/NCT02655419?term=NCT02655419&rank=1 [accessed 25 January 2018]. Tominaga, 2015, Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime–avibactam in healthy Japanese volunteers, J Infect Chemother, 21, 551, 10.1016/j.jiac.2015.04.006 Stiefelhagen, 2017, Multi-drug resistant Gram-negative pathogens: ceftazidime–avibactam is effective also in carbapenem-resistant pathogens, Arzneimitteltherapie, 35, 351 Tuon, 2018, Pharmacological aspects and spectrum of action of ceftazidime–avibactam: a systematic review, Infection, 46, 165, 10.1007/s15010-017-1096-y Chen, 2018, Novel β-lactam/β-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: a meta-analysis of randomized controlled trials, Expert Rev Anti Infect Ther, 16, 111, 10.1080/14787210.2018.1429912 Zhang, 2018, Efficacy and safety of ceftazidime–avibactam in the treatment of complicated intra-abdominal infections (CIAIs) and complicated urinary tract infections (CUTIs): a meta-analysis of randomized controlled trials, Rev Assoc Med Bras (1992), 64, 253, 10.1590/1806-9282.64.03.253 van Duin, 2018, Colistin vs. ceftazidime–avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae, Clin Infect Dis, 66, 163, 10.1093/cid/cix783 Wagenlehner, 2016, Ceftazidime–avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program, Clin Infect Dis, 63, 754, 10.1093/cid/ciw378 Torres, 2018, Ceftazidime–avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial, Lancet Infect Dis, 18, 285, 10.1016/S1473-3099(17)30747-8 Higgins, 2011, The Cochrane Collaboration's tool for assessing risk of bias in randomised trials, BMJ, 343, d5928, 10.1136/bmj.d5928 Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp [accessed 18 July 2018]. Higgins, 2008 Shields, 2017, Ceftazidime–avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia, Antimicrob Agents Chemother, 61, 10.1128/AAC.00883-17 Qin, 2017, A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia, Int J Antimicrob Agents, 49, 579, 10.1016/j.ijantimicag.2017.01.010 Mendes, 2017, Antimicrob Agents Chemother, 61 Castón, 2017, Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients, Int J Infect Dis, 59, 118, 10.1016/j.ijid.2017.03.021 Mendes, 2016, β-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime–avibactam: clinical efficacies analyzed against subsets of molecularly characterized isolates, Antimicrob Agents Chemother, 60, 1328, 10.1128/AAC.01173-15 Mazuski, 2016, Efficacy and safety of ceftazidime–avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program, Clin Infect Dis, 62, 1380, 10.1093/cid/ciw133 Carmeli, 2016, Lancet Infect Dis, 16, 661, 10.1016/S1473-3099(16)30004-4 Lucasti, 2013, Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial, J Antimicrob Chemother, 68, 1183, 10.1093/jac/dks523 Vazquez, 2012, Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study, Curr Med Res Opin, 28, 1921, 10.1185/03007995.2012.748653 Brozek JAO, Schünemann H. GRADEpro [computer program]. Version 3.2 for Windows 2008. Al-Hasan, 2012, Impact of healthcare-associated acquisition on community-onset Gram-negative bloodstream infection: a population-based study: healthcare-associated Gram-negative BSI, Eur J Clin Microbiol Infect Dis, 31, 1163, 10.1007/s10096-011-1424-6 Echols, 1999, Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis, Clin Infect Dis, 29, 113, 10.1086/520138 Thaden, 2017, Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae, Virulence, 8, 403, 10.1080/21505594.2016.1207834 Wong, 2017, Novel β-lactamase inhibitors: unlocking their potential in therapy, Drugs, 77, 615, 10.1007/s40265-017-0725-1 Mikamo, 2016, Optimal treatment for complicated intra-abdominal infections in the era of antibiotic resistance: a systematic review and meta-analysis of the efficacy and safety of combined therapy with metronidazole, Open Forum Infect Dis, 3, 10.1093/ofid/ofw143 Chiotos, 2016, Carbapenem-resistant Enterobacteriaceae infections in children, Curr Infect Dis Rep, 18, 1, 10.1007/s11908-015-0510-9 Satlin, 2014, The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies, Clin Infect Dis, 58, 1274, 10.1093/cid/ciu052 Morrill, 2015, Treatment options for carbapenem-resistant Enterobacteriaceae infections, Open Forum Infect Dis, 2, 10.1093/ofid/ofv050 Tzouvelekis, 2014, Treating infections caused by carbapenemase-producing Enterobacteriaceae, Clin Microbiol Infect, 20, 862, 10.1111/1469-0691.12697 Aghamali, 2017, Carbapenemase inhibitors, Rev Med Microbiol, 28, 104, 10.1097/MRM.0000000000000106 Lucasti, 2016, Phase 2, dose-ranging study of relebactam with imipenem–cilastatin in subjects with complicated intra-abdominal infection, Antimicrob Agents Chemother, 60, 6234, 10.1128/AAC.00633-16 Castanheira, 2017, Meropenem–vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae, Antimicrob Agents Chemother, 61, 10.1128/AAC.00567-17 Merdjan, 2017, Phase 1 study assessing the pharmacokinetic profile and safety of avibactam in patients with renal impairment, J Clin Pharmacol, 57, 211, 10.1002/jcph.793 Falcone, 2018, Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia, Expert Opin Drug Metab Toxicol, 14, 331, 10.1080/17425255.2018.1434142 Lodise, 2011, Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia, Antimicrob Agents Chemother, 55, 1606, 10.1128/AAC.01330-10 Wright, 2016, Empowering older antibiotics, Cell, 167, 301, 10.1016/j.cell.2016.09.032 Li, 2016, A randomized, phase I study to assess the safety, tolerability and pharmacokinetics of ceftazidime–avibactam in healthy Chinese subjects, Clin Drug Investig, 36, 119, 10.1007/s40261-015-0347-x Nicolau, 2015, Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens, J Antimicrob Chemother, 70, 2862, 10.1093/jac/dkv170 ClinicalTrials.gov. NCT01281462. Comparative study of coadministered ceftaroline fosamil and NXL104 vs. intravenous doripenem in adult subjects with complicated urinary tract infections. https://www.clinicaltrials.gov/ct2/show/NCT01281462?term=NCT01281462&rank=1 [accessed 6 February 2018]. ClinicalTrials.gov. NCT02497781. Evaluation of safety, pharmacokinetics and efficacy of ceftazidime and avibactam (CAZ-AVI) compared with cefepime in children from 3 months to less than 18 years of age with complicated urinary tract infections (cUTIs). https://www.clinicaltrials.gov/ct2/show/NCT02497781?term=NCT02497781&rank=1 [accessed 6 February 2018]. ClinicalTrials.gov. NCT02475733. Evaluation of safety, pharmacokinetics and efficacy of CAZ-AVI with metronidazole in children aged 3 months to 18 years old with complicated intra-abdominal infections (cIAIs). https://www.clinicaltrials.gov/ct2/show/NCT02475733?term=NCT02475733&rank=1 [accessed 6 February 2018]. ClinicalTrials.gov. NCT03329092. A study to determine the efficacy, safety and tolerability of aztreonam–avibactam (ATM-AVI) ± metronidazole (MTZ) versus meropenem (MER) ± colistin (COL) for the treatment of serious infections due to Gram negative bacteria. (REVISIT). https://www.clinicaltrials.gov/ct2/show/NCT03329092?term=NCT03329092&rank=1 [accessed 6 February 2018].